Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9666128 | 0.85 | LMNA (0.56) | LMNASMN1; SMN2NPC1GAARAB9A | |
| SCHEMBL11769775 | 0.85 | SMN1; SMN2 (0.66) | LMNASMN1; SMN2NPC1GAARAB9A | |
| Ethyl Benzoate SCHEMBL55674 | 0.84 | LMNA (0.70) | LMNASMN1; SMN2NPC1GAARAB9A | |
| Ethyl Benzoate SCHEMBL2762273 | 0.84 | LMNA (0.70) | LMNASMN1; SMN2NPC1GAARAB9A | |
| Ethyl Benzoate SCHEMBL25388294 | 0.84 | LMNA (0.70) | LMNASMN1; SMN2NPC1GAARAB9A | |
| SCHEMBL10974427 | 0.83 | ALDH1A1 (0.57) | LMNASMN1; SMN2NPC1GAARAB9A | |
| Ethyl Benzoate SCHEMBL595705 | 0.82 | LMNA (0.68) | LMNASMN1; SMN2NPC1GAARAB9A | |
| Ethyl Benzoate SCHEMBL28365249 | 0.82 | LMNA (0.68) | LMNASMN1; SMN2NPC1GAARAB9A | |
| Ethyl Benzoate SCHEMBL10340677 | 0.82 | LMNA (0.68) | LMNASMN1; SMN2NPC1GAARAB9A | |
| Ethyl Benzoate SCHEMBL9345283 | 0.82 | LMNA (0.68) | LMNASMN1; SMN2NPC1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050232915-A1 | Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer | NAKAJIMA MOTOWO | 2005-10-20 | — | — | US | disclosed |
| EP-1485131-A1 | MATRIX METALLOPROTEINASE INHIBITORS IN COMBINATION WITH HYPOTHERMIA AND/OR RADIOTHERAPY FOR THE TREATMENT OF CANCER | Novartis AG (CH) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004056353-A2 | DEVICE AND METHOD FOR DELIVERING MMP INHIBITORS | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | disclosed |
| WO-2003075959-A1 | MATRIX METALLOPROTEINASE INHIBITORS IN COMBINATION WITH HYPOTHERMIA AND/OR RADIOTHERAPY FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2003-09-18 | — | — | WO | disclosed |
| US-6500983-B2 | FOR THERAPY OF DISEASES OR CONDITIONS MEDIATED BY OVER-PRODUCTION OF OR OVER-RESPONSIVENESS TO TUMOR NECROSIS FACTOR (TNF) | NOVARTIS AG (CH) | 2002-12-31 | — | — | US | disclosed |
| EP-0929517-B1 | HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2002-06-12 | — | — | EP | disclosed |
| US-20020038045-A1 | Hydroxamic acid derivatives | NOVARTIS AG (CH) | 2002-03-28 | — | — | US | disclosed |
| EP-0929517-A1 | HYDROXAMIC ACID DERIVATIVES | Novartis AG (CH) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998014424-A1 | HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050232915-A1 | Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer | MMP3, TIMP3, MMP25 | LMNA 1706/4885SMN1; SMN2 3648/4885NPC1 3494/4885 |
| US-20020038045-A1 | Hydroxamic acid derivatives | TNF, HCAR2, HCAR1 | LMNA 4203/4885SMN1; SMN2 2678/4885NPC1 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.